Clovis Oncology Stock Beta
| CLVSDelisted Stock | USD 0.09 0.02 24.00% |
Clovis Oncology fundamentals help investors to digest information that contributes to Clovis Oncology's financial success or failures. It also enables traders to predict the movement of Clovis Stock. The fundamental analysis module provides a way to measure Clovis Oncology's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Clovis Oncology stock.
Clovis |
Clovis Oncology Company Beta Analysis
Clovis Oncology's Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Clovis Oncology Beta | 0.22 |
Most of Clovis Oncology's fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Clovis Oncology is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
CompetitionIn accordance with the recently published financial statements, Clovis Oncology has a Beta of 0.2205. This is 74.36% lower than that of the Biotechnology sector and 84.14% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Clovis Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Clovis Oncology's direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Clovis Oncology could also be used in its relative valuation, which is a method of valuing Clovis Oncology by comparing valuation metrics of similar companies.Clovis Oncology is currently under evaluation in beta category among its peers.
As returns on the market increase, Clovis Oncology's returns are expected to increase less than the market. However, during the bear market, the loss of holding Clovis Oncology is expected to be smaller as well.
Clovis Fundamentals
| Return On Asset | -0.3 | |||
| Profit Margin | (1.89) % | |||
| Operating Margin | (1.55) % | |||
| Current Valuation | 651.32 M | |||
| Shares Outstanding | 144.96 M | |||
| Shares Owned By Insiders | 1.43 % | |||
| Shares Owned By Institutions | 25.89 % | |||
| Number Of Shares Shorted | 28.49 M | |||
| Price To Earning | (8.65) X | |||
| Price To Sales | 0.11 X | |||
| Revenue | 148.76 M | |||
| Gross Profit | 115.3 M | |||
| EBITDA | (224.76 M) | |||
| Net Income | (264.52 M) | |||
| Cash And Equivalents | 94.58 M | |||
| Cash Per Share | 0.65 X | |||
| Total Debt | 436.77 M | |||
| Debt To Equity | 810.00 % | |||
| Current Ratio | 1.17 X | |||
| Book Value Per Share | (2.89) X | |||
| Cash Flow From Operations | (196.06 M) | |||
| Short Ratio | 4.63 X | |||
| Earnings Per Share | (2.08) X | |||
| Price To Earnings To Growth | 0.13 X | |||
| Target Price | 2.0 | |||
| Number Of Employees | 413 | |||
| Beta | 0.22 | |||
| Market Capitalization | 11.77 M | |||
| Total Asset | 472.83 M | |||
| Retained Earnings | (2.3 B) | |||
| Working Capital | 464.12 M | |||
| Current Asset | 539.7 M | |||
| Current Liabilities | 75.58 M | |||
| Z Score | -5.6 | |||
| Net Asset | 472.83 M |
About Clovis Oncology Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Clovis Oncology's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Clovis Oncology using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Clovis Oncology based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in real. You can also try the Idea Breakdown module to analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes.
Other Consideration for investing in Clovis Stock
If you are still planning to invest in Clovis Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Clovis Oncology's history and understand the potential risks before investing.
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Risk-Return Analysis View associations between returns expected from investment and the risk you assume | |
| Headlines Timeline Stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments |